Pier Vincenzo Colli, Chief Executive Officer at A
Post# of 72445
(Total Views: 440)
Posted On: 07/23/2019 5:26:02 PM
Pier Vincenzo Colli, Chief Executive Officer at Alfasigma.
"We will also closely follow Innovation’s progress in developing oral Brilacidin, as we remain highly interested in novel oral IBD treatments. This agreement is a further step in strengthening our pipeline.”
Leo per Jan22 PR
"As a first step, a simple oral formulation of Brilacidin, may be expediently tested in human volunteers, while the refined oral dosage form of Brilacidin is developed in parallel. The anticipated clinical study’s primary goals include assessing safety and toleration, pharmacokinetics, and the effects of Brilacidin on the gut’s microbiome.
My guess is a another new License agreement for oral IBD will come just after the simple oral formulation is tested in healthy volunteers. I think It aligns with what Pier said.
"We will also closely follow Innovation’s progress in developing oral Brilacidin, as we remain highly interested in novel oral IBD treatments. This agreement is a further step in strengthening our pipeline.”
Leo per Jan22 PR
"As a first step, a simple oral formulation of Brilacidin, may be expediently tested in human volunteers, while the refined oral dosage form of Brilacidin is developed in parallel. The anticipated clinical study’s primary goals include assessing safety and toleration, pharmacokinetics, and the effects of Brilacidin on the gut’s microbiome.
My guess is a another new License agreement for oral IBD will come just after the simple oral formulation is tested in healthy volunteers. I think It aligns with what Pier said.
(4)
(0)